The short-term outcomes with multikinase inhibitors with activity against RET compared to EGFR/ALK TKIs in EGFR-mutant/ALK-rearranged NSCLC, strongly suggest that there is a need for more selective and potent RET targeted agents as monotherapy or in combination in order to enhance activity (116). The gene discussed is RET; the disease is non-small cell lung carcinoma.